MCG
BIOR

McCollum Christoferson Group’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

McCollum Christoferson Group’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-53
Closed -$15K – 75
2022
Q1 		$15K Buy
+53
New +$20.1K ﹤0.01% 74

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

McCollum Christoferson Group's BIOR Position: Q2 2022 in Review

McCollum Christoferson Group sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q2 2022, closing a stake of 53 shares — an estimated $15K sold.

McCollum Christoferson Group first reported a position in BIOR in Q1 2022 and held it in 1 quarter. The position peaked at $15K in Q1 2022. 46 funds tracked by Wall St. Rank hold BIOR as of Q2 2022.

  • McCollum Christoferson Group reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • McCollum Christoferson Group sold 53 Biora Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $15K.
  • McCollum Christoferson Group first reported a position in Biora Therapeutics, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • McCollum Christoferson Group's Biora Therapeutics, Inc. Common Stock position peaked at $15K in Q1 2022.
  • 46 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q2 2022.

Based on McCollum Christoferson Group's 13F filing for Q2 2022, filed 10 Aug 2022.